Results 131 to 140 of about 50,472 (297)

Factors Associated With Rectal Spacer Use in Prostate Cancer Patients Receiving Radiation Therapy

open access: yesCancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Background/Objective Prostate cancer is a leading cause of cancer‐related death among men in the United States. However, the influence of demographic, socioeconomic, regional, and treatment‐related factors on rectal spacer use among men treated with radiation therapy remains largely unexplored in the literature.
Ryan A. Hankins   +5 more
wiley   +1 more source

Intravesical prostatic protrusion as a predictor of acute urinary retention following stereotactic body radiation therapy for localised prostate cancer: a retrospective study

open access: yesOncologie
Predictors of acute urinary retention after stereotactic body radiotherapy (SBRT) for localised prostate cancer remain undefined. This study aimed to evaluate the association between intravesical prostatic protrusion (IPP) and its occurrence.
Ito Makoto   +7 more
doaj   +1 more source

Fruquintinib Plus TAS‐102 With or Without SBRT as Third‐ Or Later‐Line Therapy for Metastatic Colorectal Cancer: Preliminary Results From a Prospective Phase II Trial

open access: yesCancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Both fruquintinib and TAS‐102 monotherapies are guideline‐recommended for third‐line treatment of metastatic colorectal cancer (mCRC). This study aimed to analyze the preliminary outcomes of fruquintinib combined with TAS‐102, with or without stereotactic body radiation therapy (SBRT), as a third‐ or later‐line therapy for mCRC.
Yi Wang   +19 more
wiley   +1 more source

Promising Stereotactic Body Radiotherapy in NSCLC [PDF]

open access: yesJournal of Thoracic Oncology, 2020
Yajing, Du   +3 more
openaire   +2 more sources

Programmed Death‐Ligand 1 Expression Predicts Poor Prognosis in Patients With Early‐Stage Non‐Small‐Cell Lung Cancer Undergoing Stereotactic Body Radiotherapy

open access: yesThoracic Cancer, Volume 17, Issue 9, May 2026.
PD‐L1 expression is independently associated with inferior survival outcomes and increased regional recurrence in early‐stage NSCLC treated with SBRT. These findings suggest that PD‐L1 status serves as a prognostic biomarker for identifying high‐risk patients who may benefit from intensified systemic strategies, such as combining SBRT with ...
Jongmoo Park   +5 more
wiley   +1 more source

Cytoreductive nephrectomy in the era of immune‐checkpoint inhibitors: back to the future?

open access: yesBJU International, Volume 137, Issue 5, Page 763-769, May 2026.
Objective To investigate the role of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC) treated with immune‐checkpoint inhibitors (ICIs). Methods A narrative review was carried out using PubMed and searching for English articles published from January 2015 to May 2025.
Rocco Simone Flammia   +8 more
wiley   +1 more source

Editorial: Stereotactic body radiotherapy for prostate cancer

open access: yesFrontiers in Oncology, 2022
Amar U. Kishan   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy